Azarova AM, Gautam G and George RE, ‘Emerging Importance of ALK in Neuroblastoma’ (2011) 21 Seminars in Cancer Biology 267 <https://doi.org/10.1016/j.semcancer.2011.09.005>
Beierle EA, ‘MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK)’ 3 Frontiers in bioscience (Elite edition) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/>
Bell E and others, ‘MYCN Oncoprotein Targets and Their Therapeutic Potential’ (2010) 293 Cancer Letters 144 <https://doi.org/10.1016/j.canlet.2010.01.015>
Bender S and others, ‘Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas’ (2013) 24 Cancer Cell 660 <https://doi.org/10.1016/j.ccr.2013.10.006>
Berry T and others, ‘The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma’ (2012) 22 Cancer Cell 117 <https://doi.org/10.1016/j.ccr.2012.06.001>
Bleggi-Torres LF and others, ‘Accuracy of the Smear Technique in the Cytological Diagnosis of 650 Lesions of the Central Nervous System’ (2001) 24 Diagnostic Cytopathology 293 <https://doi.org/10.1002/dc.1062>
Blümcke I and others, ‘Low-Grade Epilepsy-Associated Neuroepithelial Tumours — the 2016 WHO Classification’ (2016) 12 Nature Reviews Neurology 732 <https://doi.org/10.1038/nrneurol.2016.173>
Brodeur GM, ‘Neuroblastoma: Biological Insights into a Clinical Enigma’ (2003) 3 Nature Reviews Cancer 203 <https://doi.org/10.1038/nrc1014>
Brodeur GM and Bagatell R, ‘Mechanisms of Neuroblastoma Regression’ (2014) 11 Nature Reviews Clinical Oncology 704 <https://doi.org/10.1038/nrclinonc.2014.168>
Brown CE and others, ‘Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy’ (2016) 375 New England Journal of Medicine 2561 <https://doi.org/10.1056/NEJMoa1610497>
Buckner T, Blatt J and Smith SV, ‘The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience’ (2006) 9 Pediatric and Developmental Pathology 374 <https://doi.org/10.2350/06-02-0047.1>
Burkhart CA and others, ‘Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma’ (2003) 95 JNCI Journal of the National Cancer Institute 1394 <https://doi.org/10.1093/jnci/djg045>
Chen L and others, ‘P53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma’ (2010) 70 Cancer Research 1377 <https://doi.org/10.1158/0008-5472.CAN-09-2598>
Chhabda S and others, ‘The 2016 World Health Organization Classification of Tumours of the Central Nervous System: What the Paediatric Neuroradiologist Needs to Know’ (2016) 6 Quantitative Imaging in Medicine and Surgery 486 <https://doi.org/10.21037/qims.2016.10.01>
‘Children’s Cancer Statistics | Cancer Research UK’ <http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers>
Cossu I and others, ‘Neuroblastoma-Targeted Nanocarriers Improve Drug Delivery and Penetration, Delay Tumor Growth and Abrogate Metastatic Diffusion’ (2015) 68 Biomaterials 89 <https://doi.org/10.1016/j.biomaterials.2015.07.054>
Ellison DW and others, ‘β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children’s Cancer Study Group Brain Tumour Committee’ (2005) 23 Journal of Clinical Oncology 7951 <https://doi.org/10.1200/JCO.2005.01.5479>
Evans AE, Baum E and Chard R, ‘Do Infants with Stage IV-S Neuroblastoma Need Treatment?’ (1981) 56 Archives of Disease in Childhood 271 <https://doi.org/10.1136/adc.56.4.271>
Fisher J and others, ‘Avoidance of On-Target Off-Tumor Activation Using a Co-Stimulation-Only Chimeric Antigen Receptor’ (2017) 25 Molecular Therapy 1234 <https://doi.org/10.1016/j.ymthe.2017.03.002>
Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop, ‘Amplification of N-Myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage’ (1984) 224 Science 1121 <http://www.jstor.org/stable/1692440>
Ghorashian S, Amrolia P and Veys P, ‘Open Access? Widening Access to Chimeric Antigen Receptor (CAR) Therapy for ALL’ (2018) 66 Experimental Hematology 5 <https://doi.org/10.1016/j.exphem.2018.07.002>
Gibson P and others, ‘Subtypes of Medulloblastoma Have Distinct Developmental Origins’ (2010) 468 Nature 1095 <https://doi.org/10.1038/nature09587>
Goschzik T and others, ‘Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma’ [2017] Journal of Neuropathology & Experimental Neurology <https://doi.org/10.1093/jnen/nlw116>
Greaves MF and Wiemels J, ‘Origins of Chromosome Translocations in Childhood Leukaemia’ (2003) 3 Nature Reviews Cancer 639 <https://doi.org/10.1038/nrc1164>
Guglielmi L and others, ‘MYCN Gene Expression Is Required for the Onset of the Differentiation Programme in Neuroblastoma Cells’ (2014) 5 Cell Death & Disease e1081 <https://doi.org/10.1038/cddis.2014.42>
Gump JM and others, ‘Identification of Targets for Rational Pharmacological Therapy in Childhood Craniopharyngioma’ (2015) 3 Acta Neuropathologica Communications <https://doi.org/10.1186/s40478-015-0211-5>
Hanahan D and Weinberg RA, ‘The Hallmarks of Cancer’ (2000) 100 Cell 57 <https://doi.org/10.1016/S0092-8674(00)81683-9>
Hanahan D and Weinberg RA, ‘Hallmarks of Cancer: The Next Generation’ (2011) 144 Cell 646 <https://doi.org/10.1016/j.cell.2011.02.013>
Hashizume R and others, ‘Pharmacologic Inhibition of Histone Demethylation as a Therapy for Pediatric Brainstem Glioma’ (2014) 20 Nature Medicine 1394 <https://doi.org/10.1038/nm.3716>
Hasle H and Niemeyer CM, ‘Advances in the Prognostication and Management of Advanced MDS in Children’ (2011) 154 British Journal of Haematology 185 <https://doi.org/10.1111/j.1365-2141.2011.08724.x>
Hill RM and others, ‘Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease’ (2015) 27 Cancer Cell 72 <https://doi.org/10.1016/j.ccell.2014.11.002>
Hourigan CS and Karp JE, ‘Minimal Residual Disease in Acute Myeloid Leukaemia’ (2013) 10 Nature Reviews Clinical Oncology 460 <https://doi.org/10.1038/nrclinonc.2013.100>
Huang M and Weiss WA, ‘Neuroblastoma and MYCN’ (2013) 3 Cold Spring Harbor Perspectives in Medicine a014415 <https://doi.org/10.1101/cshperspect.a014415>
Huber K, Kalcheim C and Unsicker K, ‘The Development of the Chromaffin Cell Lineage from the Neural Crest’ (2009) 151 Autonomic Neuroscience 10 <https://doi.org/10.1016/j.autneu.2009.07.020>
Hubert CG and others, ‘A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found’ (2016) 76 Cancer Research 2465 <https://doi.org/10.1158/0008-5472.CAN-15-2402>
Hunger SP and Mullighan CG, ‘Acute Lymphoblastic Leukemia in Children’ (2015) 373 New England Journal of Medicine 1541 <https://doi.org/10.1056/NEJMra1400972>
International Agency for Research on Cancer, WHO Classification of Tumours of the Central Nervous System (David N Louis and others eds, Revised 4th edition, International Agency for Research on Cancer 2016)
Johnson LA and June CH, ‘Driving Gene-Engineered T Cell Immunotherapy of Cancer’ (2017) 27 Cell Research 38 <https://doi.org/10.1038/cr.2016.154>
Kirsti Sirkiä, Ulla M. Saarinen‐Pihkala, Liisa Hovi, Hannu Sariola, ‘Autopsy in Children with Cancer Who Die While in Terminal Care’ (1998) 30 Medical and Pediatric Oncology 284 <https://doi.org/10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B>
Klebanoff CA, Rosenberg SA and Restifo NP, ‘Prospects for Gene-Engineered T Cell Immunotherapy for Solid Cancers’ (2016) 22 Nature Medicine 26 <https://doi.org/10.1038/nm.4015>
Koebel CM and others, ‘Adaptive Immunity Maintains Occult Cancer in an Equilibrium State’ (2007) 450 Nature 903 <https://doi.org/10.1038/nature06309>
Korshunov, AndreySturm, DominikRyzhova, MarinaHovestadt, VolkerGessi, Marco, ‘Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR), Ependymoblastoma, and Medulloepithelioma Share Molecular Similarity and Comprise a Single Clinicopathological Entity’ 128 Acta Neuropathologica 279 <https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&accountid=14511>
Kotrova M and others, ‘Is Next-Generation Sequencing the Way to Go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?’ (2017) 21 Molecular Diagnosis & Therapy 481 <https://doi.org/10.1007/s40291-017-0277-9>
Larson JD and others, ‘Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression’ [2018] Cancer Cell <https://doi.org/10.1016/j.ccell.2018.11.015>
Lee TI and Young RA, ‘Transcriptional Regulation and Its Misregulation in Disease’ (2013) 152 Cell 1237 <https://doi.org/10.1016/j.cell.2013.02.014>
Lewis PW and others, ‘Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma’ (2013) 340 Science 857 <https://doi.org/10.1126/science.1232245>
Liu Z and Thiele CJ, ‘ALK and MYCN: When Two Oncogenes Are Better than One’ (2012) 21 Cancer Cell 325 <https://doi.org/10.1016/j.ccr.2012.03.004>
Lord CJ and Ashworth A, ‘Biology-Driven Cancer Drug Development: Back to the Future’ (2010) 8 BMC Biology <https://doi.org/10.1186/1741-7007-8-38>
Lu B and others, ‘Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials’ (2016) 8 Cancers <https://doi.org/10.3390/cancers8090082>
Mackall CL, Merchant MS and Fry TJ, ‘Immune-Based Therapies for Childhood Cancer’ (2014) 11 Nature Reviews Clinical Oncology 693 <https://doi.org/10.1038/nrclinonc.2014.177>
Majzner RG, Heitzeneder S and Mackall CL, ‘Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers’ (2017) 31 Cancer Cell 476 <https://doi.org/10.1016/j.ccell.2017.03.002>
Marabelle A and others, ‘Hypercalcemia and 13- -Retinoic Acid in Post-Consolidation Therapy of Neuroblastoma’ (2009) 52 Pediatric Blood & Cancer 280 <https://doi.org/10.1002/pbc.21768>
Martinez-Barbera JP and Andoniadou CL, ‘Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma’ (2016) 34 STEM CELLS 268 <https://doi.org/10.1002/stem.2267>
Martinez-Barbera JP and Buslei R, ‘Adamantinomatous Craniopharyngioma: Pathology, Molecular Genetics and Mouse Models’ (2015) 28 Journal of Pediatric Endocrinology and Metabolism <https://doi.org/10.1515/jpem-2014-0442>
Matthay KK and others, ‘Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13- -Retinoic Acid’ (1999) 341 New England Journal of Medicine 1165 <https://doi.org/10.1056/NEJM199910143411601>
Milne TA, ‘Mouse Models of MLL Leukemia: Recapitulating the Human Disease’ (2017) 129 Blood 2217 <https://doi.org/10.1182/blood-2016-10-691428>
Morsut L and others, ‘Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors’ (2016) 164 Cell 780 <https://doi.org/10.1016/j.cell.2016.01.012>
Mossé YP and others, ‘Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene’ (2008) 455 Nature 930 <https://doi.org/10.1038/nature07261>
Nataliya Zhukova, ‘Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma’ (2013) 31 Journal of Clinical Oncology <https://doi.org/10.1200/JCO.2012.48.5052>
‘Nature Reviews Immunology’ (2012) 12 <https://www.nature.com/nri/volumes/12/issues/4>
Niemeyer CM and Kratz CP, ‘Paediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukaemia: Molecular Classification and Treatment Options’ (2008) 140 British Journal of Haematology 610 <https://doi.org/10.1111/j.1365-2141.2007.06958.x>
Niklison-Chirou MV and others, ‘TAp73 Is a Marker of Glutamine Addiction in Medulloblastoma’ (2017) 31 Genes & Development 1738 <https://doi.org/10.1101/gad.302349.117>
Northcott PA and others, ‘The Clinical Implications of Medulloblastoma Subgroups’ (2012) 8 Nature Reviews Neurology 340 <https://doi.org/10.1038/nrneurol.2012.78>
O’Connor D and others, ‘Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia’ (2018) 36 Journal of Clinical Oncology 34 <https://doi.org/10.1200/JCO.2017.74.0449>
——, ‘Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia’ (2018) 36 Journal of Clinical Oncology 34 <https://doi.org/10.1200/JCO.2017.74.0449>
Pastorino F and others, ‘Ligand-Targeted Liposomal Therapies of Neuroblastoma’ (2007) 14 Current Medicinal Chemistry 3070 <https://doi.org/10.2174/092986707782793916>
Pathania M and others, ‘H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas’ (2017) 32 Cancer Cell 684 <https://doi.org/10.1016/j.ccell.2017.09.014>
Pfister S and others, ‘Novel Genomic Amplification Targeting the microRNA Cluster at 19q13.42 in a Pediatric Embryonal Tumor with Abundant Neuropil and True Rosettes’ (2009) 117 Acta Neuropathologica 457 <https://doi.org/10.1007/s00401-008-0467-y>
Phoenix TN and others, ‘Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype’ (2016) 29 Cancer Cell 508 <https://doi.org/10.1016/j.ccell.2016.03.002>
Qasim W and others, ‘Molecular Remission of Infant B-ALL after Infusion of Universal TALEN Gene-Edited CAR T Cells’ (2017) 9 Science Translational Medicine <https://doi.org/10.1126/scitranslmed.aaj2013>
Qiao J and others, ‘PI3K/AKT and ERK Regulate Retinoic Acid-Induced Neuroblastoma Cellular Differentiation’ (2012) 424 Biochemical and Biophysical Research Communications 421 <https://doi.org/10.1016/j.bbrc.2012.06.125>
Rasaiyaah J and others, ‘TCRαβ/CD3 Disruption Enables CD3-Specific Antileukemic T Cell Immunotherapy’ (2018) 3 JCI Insight <https://doi.org/10.1172/jci.insight.99442>
Reynolds CP and others, ‘Retinoid Therapy of High-Risk Neuroblastoma’ (2003) 197 Cancer Letters 185 <https://doi.org/10.1016/S0304-3835(03)00108-3>
Richmond A and Su Y, ‘Mouse Xenograft Models vs GEM Models for Human Cancer Therapeutics’ (2008) 1 Disease Models and Mechanisms 78 <https://doi.org/10.1242/dmm.000976>
Sadelain M, Rivière I and Riddell S, ‘Therapeutic T Cell Engineering’ (2017) 545 Nature 423 <https://doi.org/10.1038/nature22395>
Schwab M, ‘MYCN in Neuronal Tumours’ (2004) 204 Cancer Letters 179 <https://doi.org/10.1016/S0304-3835(03)00454-3>
Schwalbe EC and others, ‘Novel Molecular Subgroups for Clinical Classification and Outcome Prediction in Childhood Medulloblastoma: A Cohort Study’ (2017) 18 The Lancet Oncology 958 <https://doi.org/10.1016/S1470-2045(17)30243-7>
Schwalbe EdC and others, ‘Histologically Defined Central Nervous System Primitive Neuro-Ectodermal Tumours (CNS-PNETs) Display Heterogeneous DNA Methylation Profiles and Show Relationships to Other Paediatric Brain Tumour Types’ (2013) 126 Acta Neuropathologica 943 <https://doi.org/10.1007/s00401-013-1206-6>
Schwartzentruber J and others, ‘Driver Mutations in Histone H3.3 and Chromatin Remodelling Genes in Paediatric Glioblastoma’ (2012) 482 Nature 226 <https://doi.org/10.1038/nature10833>
Sidell N, ‘Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro’ [1982] JNCI: Journal of the National Cancer Institute <https://doi.org/10.1093/jnci/68.4.589>
Slany RK, ‘The Molecular Mechanics of Mixed Lineage Leukemia’ (2016) 35 Oncogene 5215 <https://doi.org/10.1038/onc.2016.30>
Stone TJ and Jacques TS, ‘Medulloblastoma: Selecting Children for Reduced Treatment’ (2015) 41 Neuropathology and Applied Neurobiology 106 <https://doi.org/10.1111/nan.12193>
Strebhardt K and Ullrich A, ‘Paul Ehrlich’s Magic Bullet Concept: 100 Years of Progress’ (2008) 8 Nature Reviews Cancer 473 <https://doi.org/10.1038/nrc2394>
Sturm D and others, ‘Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma’ (2012) 22 Cancer Cell 425 <https://doi.org/10.1016/j.ccr.2012.08.024>
——, ‘New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs’ (2016) 164 Cell 1060 <https://doi.org/10.1016/j.cell.2016.01.015>
Taylor, Michael DNorthcott, Paul AKorshunov, AndreyRemke, MarcCho, Yoon-jae, ‘Molecular Subgroups of Medulloblastoma: The Current Consensus’ 123 Acta Neuropathologica 465 <https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprimo>
Vogelstein B and others, ‘Cancer Genome Landscapes’ (2013) 339 Science 1546 <https://doi.org/10.1126/science.1235122>
——, ‘Cancer Genome Landscapes’ (2013) 339 Science 1546 <https://doi.org/10.1126/science.1235122>
Vora A and others, ‘Treatment Reduction for Children and Young Adults with Low-Risk Acute Lymphoblastic Leukaemia Defined by Minimal Residual Disease (UKALL 2003): A Randomised Controlled Trial’ (2013) 14 The Lancet Oncology 199 <https://doi.org/10.1016/S1470-2045(12)70600-9>
——, ‘Augmented Post-Remission Therapy for a Minimal Residual Disease-Defined High-Risk Subgroup of Children and Young People with Clinical Standard-Risk and Intermediate-Risk Acute Lymphoblastic Leukaemia (UKALL 2003): A Randomised Controlled Trial’ (2014) 15 The Lancet Oncology 809 <https://doi.org/10.1016/S1470-2045(14)70243-8>
Wegman-Ostrosky T and Savage SA, ‘The Genomics of Inherited Bone Marrow Failure: From Mechanism to the Clinic’ (2017) 177 British Journal of Haematology 526 <https://doi.org/10.1111/bjh.14535>
Weinberg RA, The Biology of Cancer (2nd ed, Garland Science 2014)
Wright JH, ‘NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED’ (1910) 12 The Journal of Experimental Medicine <https://doi.org/10.1084/jem.12.4.556>
Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing, ‘PHOX2B Is Associated with Neuroblastoma Cell Differentiation’ 31 Cancer Biotherapy & Radiopharmaceuticals 44 <https://doi.org/10.1089/cbr.2015.1952>
Yong CSM and others, ‘CAR T-Cell Therapy of Solid Tumors’ (2017) 95 Immunology and Cell Biology 356 <https://doi.org/10.1038/icb.2016.128>
Zelent A, Greaves M and Enver T, ‘Role of the TEL-AML1 Fusion Gene in the Molecular Pathogenesis of Childhood Acute Lymphoblastic Leukaemia’ (2004) 23 Oncogene 4275 <https://doi.org/10.1038/sj.onc.1207672>
Zhu S and others, ‘Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis’ (2012) 21 Cancer Cell 362 <https://doi.org/10.1016/j.ccr.2012.02.010>
